TR200003589T2 - Biyolojik olarak aktif bileşim. - Google Patents

Biyolojik olarak aktif bileşim.

Info

Publication number
TR200003589T2
TR200003589T2 TR2000/03589T TR200003589T TR200003589T2 TR 200003589 T2 TR200003589 T2 TR 200003589T2 TR 2000/03589 T TR2000/03589 T TR 2000/03589T TR 200003589 T TR200003589 T TR 200003589T TR 200003589 T2 TR200003589 T2 TR 200003589T2
Authority
TR
Turkey
Prior art keywords
biologically active
active composition
ester
chemical reactions
well
Prior art date
Application number
TR2000/03589T
Other languages
English (en)
Inventor
Lindahl Ake
Hagslatt Hakan
Benediktsson Catharina
Bryland Rickard
Original Assignee
Bioglan Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioglan Ab filed Critical Bioglan Ab
Publication of TR200003589T2 publication Critical patent/TR200003589T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Bulus, biyolojik aktif eczayi serbest birakacak, yeni bir biyolojik olarak aktif bilesim konusundadir. Söz konusu biyolojik olarak aktif ecza iyice doygun bir durumda sivi ve/veya kati kristalin matrisli olmayan ester ve/veya poliester bir tasiyici içinde eritilmis ve/veya ayrilmis durumdadir ve biyolojik olarak aktif eczanin tortu (çökelti) haline gelmesi büyük ölçüde, veya tamamen bununla engellenmistir. Söz konusu iyice doygun durum, bir veya daha fazla baslangiç tasiyici maddesinin, bu sekilde kimyasal reaksiyonlara tabi tutularak, bir ester ve/veya poliester matrisinin ortaya çikartilmasi suretiyle elde edilmekte ve biyolojik olarak aktif ecza, kimyasal reaksiyonlar tamamlandiktan sonra ilave edilmektedir.
TR2000/03589T 1998-05-14 1999-05-12 Biyolojik olarak aktif bileşim. TR200003589T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801704A SE9801704D0 (sv) 1998-05-14 1998-05-14 Biologically active composition

Publications (1)

Publication Number Publication Date
TR200003589T2 true TR200003589T2 (tr) 2001-03-21

Family

ID=20411318

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03589T TR200003589T2 (tr) 1998-05-14 1999-05-12 Biyolojik olarak aktif bileşim.

Country Status (20)

Country Link
US (1) US6537576B1 (tr)
EP (1) EP1082102B1 (tr)
JP (1) JP2002514587A (tr)
KR (1) KR100592971B1 (tr)
CN (1) CN1309553A (tr)
AT (1) ATE310500T1 (tr)
AU (1) AU736480B2 (tr)
CA (1) CA2331527C (tr)
DE (2) DE1082102T1 (tr)
ES (1) ES2155048T3 (tr)
GR (1) GR20010300013T1 (tr)
HU (1) HUP0102426A2 (tr)
IL (2) IL139576A0 (tr)
NO (1) NO20005724L (tr)
NZ (1) NZ508073A (tr)
PL (1) PL344051A1 (tr)
SE (1) SE9801704D0 (tr)
TR (1) TR200003589T2 (tr)
WO (1) WO1999058108A1 (tr)
ZA (1) ZA200006474B (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010033858A1 (en) * 2000-02-29 2001-10-25 Jie Zhang Transdermal drug patch
JP2009540019A (ja) 2006-06-14 2009-11-19 ドクター・レディーズ・ラボラトリーズ・リミテッド 局所組成物
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
EP2742934A1 (en) 2008-10-06 2014-06-18 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
EP3473615B1 (en) 2013-02-28 2022-01-19 Journey Medical Corporation Glycopyrrolate salts
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD217989A1 (de) 1983-08-09 1985-01-30 Univ Ernst Moritz Arndt Verfahren zur herstellung einer pharmazeutischen zubereitung
US4940701A (en) * 1984-01-25 1990-07-10 Beecham Group P.L.C. Topical drug release system
AR246186A1 (es) 1989-11-17 1994-07-29 Beta Pharm Co Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica.
SE9502244D0 (sv) * 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
GB2306885B (en) * 1995-11-08 1999-07-14 Reckitt & Colmann Prod Ltd Supersaturated Pharmaceutical Compositions

Also Published As

Publication number Publication date
GR20010300013T1 (en) 2001-04-30
NO20005724D0 (no) 2000-11-13
DE69928524D1 (de) 2005-12-29
IL139576A0 (en) 2002-02-10
CN1309553A (zh) 2001-08-22
CA2331527C (en) 2010-04-13
EP1082102A1 (en) 2001-03-14
NZ508073A (en) 2002-12-20
DE1082102T1 (de) 2001-09-06
KR20010052348A (ko) 2001-06-25
WO1999058108A1 (en) 1999-11-18
SE9801704D0 (sv) 1998-05-14
ZA200006474B (en) 2001-09-04
CA2331527A1 (en) 1999-11-18
ES2155048T3 (es) 2006-06-16
IL139576A (en) 2007-07-04
AU736480B2 (en) 2001-07-26
ES2155048T1 (es) 2001-05-01
DE69928524T2 (de) 2006-08-10
ATE310500T1 (de) 2005-12-15
PL344051A1 (en) 2001-09-24
KR100592971B1 (ko) 2006-06-23
JP2002514587A (ja) 2002-05-21
NO20005724L (no) 2001-01-09
US6537576B1 (en) 2003-03-25
AU4405099A (en) 1999-11-29
EP1082102B1 (en) 2005-11-23
HUP0102426A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
Kuo et al. Characterization of the high‐affinity Ca2+ binding sites in the L‐type Ca2+ channel pore in rat phaeochromocytoma cells.
AU8000301A (en) Integrated microarray devices
TR200401645T4 (tr) Sıvı formülasyonlar.
TR200000897T2 (tr) Bir kişisel iletişim asistanı kullanılarak bilgi işlem yöntemi
TR199903315T2 (tr) Kati paroksetin dagilimlarinin imali için yeni proses.
BR0210184A (pt) Dispositivo de exibição com camada mista organometálica
TR200003589T2 (tr) Biyolojik olarak aktif bileşim.
MX9803308A (es) Metodos y composiciones para la deteccion de secuencias especificas de nucleotidos.
ATE448263T1 (de) Monomer-, oligomer- und pi-konjugierte polymerverbindungen und photovoltaische zellen, welche diese enthalten
DE60307520D1 (de) Neue polyhydroxyalkanoate, die amidgruppen, sulfonsäuregruppen und sulfontestergruppen enthalten, ladungssteuermittel und toner
ATE380249T1 (de) Stabiele transfizierte zellen zum auffinden von wirkstoffen, die die mrna stabilität beeinflussen
BR0009530A (pt) Sìntese de polinucleotìdeos usando uma enzima de processamento
BR9810844A (pt) Processo para detectar um microorganismo em uma amostra lìquida de teste, e, dispositivo de ensaio para conduzir o processo
ES2145958T3 (es) Procedimiento continuo para la preparacion de 4-amino-2,2,6,6-tetrametilpiperidina.
BRPI0415496A (pt) microdisposição de oligonucleotìdeo
NO20020572L (no) Flytende farmasöytisk sammensetning som omfatter en aktiv fase og en ikke-aktiv fase
PT1003525E (pt) Composicao e metodo para a regulacao da proliferacao e da morte celular
DE60332600D1 (de) Selektive elution von immobilisierten multiplexierten primerverlängerungsprodukten
FI980716A0 (fi) Arrangemang i samband med en hydraulvaetskedriven slaganordning, saosom t.ex. i en krossanordning
TR200001423T2 (tr) Erimiş paroksetin içeren yeni formülasyonlar
DE60321801D1 (de) Sphäroide, deren herstellungsverfahren und sphäroidenhaltige arzneimittel
TR200003588T2 (tr) Biyolojik olarak aktif bileşim
Kawai et al. Hole transfer through DNA monitored by transient absorption of phenothiazine radical cation
Büsch et al. Dissecting the differences between the α and β anomers of the oxidative DNA lesion FaPydG
MY120255A (en) 1-(4-arylpiperazin-1-yl)-hertz-[n-(alpha, hertz-dicarboximido)]-alkanes useful as uro-selective (alpha1)-adrenoceptor blockers